Method for predicting responsiveness to a treatment with an egfr inhibitor
AssigneesIntegragen, Institut National De La Sante Et De La Recherche Medicale (Inserm), Centre National de la Recherche Scientifque (CNRS), Assistance Publique-Hopitaux de Paris, Universite Paris Descartes
InventorsThomas Rio Frio, Pierre Laurent-Puig, Sandrine Imbeaud
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
Claims22
-30. (canceled)
An in vitro method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level of hsa-miR-31-3p (SEQ ID NO:1) miRNA in a sample of said patient.
A kit for determining whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, comprising or consisting of:
- a) reagents for determining the expression level of hsa-miR-31-3p (SEQ ID NO:1) miRNA in a sample of said patient, and
- b) reagents for determining the BRAF status of the patient.
A method for treating a patient affected with a cancer, which method comprises:
- (i) determining whether the patient is likely to respond to an EGFR inhibitor, by determining the expression level of hsa-miR-31-3p (SEQ ID NO:1) miRNA in a sample of said patient, and
- (ii) administering an EGFR inhibitor to said patient if the patient has been determined to be likely to respond to the EGFR inhibitor.
Dependencies are inferred from the claim text.